Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Cancer Cell. 2024 Sep 9;42(9):1491-1493. doi: 10.1016/j.ccell.2024.08.014.
Combination immunotherapy improves outcomes in metastatic melanoma, but the underlying mechanisms remain unclear. In this issue of Cancer Cell, Wang et al. report dynamics and transcriptional states of CD8 T cell clones over time in patients treated with anti-PD-1, anti-CTLA-4, or a combination of the two. These findings have important implications for understanding and monitoring combination immunotherapy.
联合免疫疗法改善了转移性黑色素瘤的预后,但潜在机制仍不清楚。在本期《癌细胞》杂志上,Wang 等人报告了接受抗 PD-1、抗 CTLA-4 或两者联合治疗的患者体内 CD8 T 细胞克隆随时间的动态变化和转录状态。这些发现对理解和监测联合免疫疗法具有重要意义。